Polymorphism 2184A/G in the AGER gene is not associated with diabetic retinopathy in Han Chinese patients with type 2 diabetes

Jian Li¹,²,*, Wei Cai³,*, Wei Zhang⁴, Wei-Feng Zhu⁵, Ying Liu¹, Li-Xia Yue¹, Ling-Yan Zhu¹, Jun-Ren Xiao¹, Jian-Ying Liu¹ and Ji-Xiong Xu¹

Abstract

**Objective:** To assess the association between the 2184A/G polymorphism in the advanced glycosylation end product-specific receptor (AGER) gene and the susceptibility to diabetic retinopathy (DR) in Han Chinese patients with type 2 diabetes mellitus (T2DM).

**Methods:** This cross-sectional genotyping study included patients with T2DM with and without DR. Genotype and allele frequencies of the 2184A/G polymorphism were detected using polymerase chain reaction–restriction fragment-length polymorphism analysis.

**Results:** This study included 943 patients with T2DM (285 with DR [DR group] and 658 without DR [NDR group]). There were no significant differences in age, sex, body mass index, total cholesterol, high-density lipoprotein cholesterol, low-density lipoprotein cholesterol, diastolic blood pressure, glycosylated haemoglobin, fasting blood glucose, postprandial 2-hour blood glucose, and triglycerides between the two groups. The duration of T2DM and systolic blood pressure were significantly increased in the DR group compared with the NDR group. No significant differences were found in allele (A and G) and genotype (AA, AG and GG) frequencies of the 2184A/G polymorphism between the two groups.

¹Department of Endocrinology and Metabolism, First Affiliated Hospital of Nanchang University, Nanchang, Jiangxi Province, China
²Department of Endocrinology and Metabolism, First People’s Hospital of Xinxiang City, Xinxiang, Henan Province, China
³Department of Medical Biology, Jiangxi Medical College of Nanchang University, Nanchang, Jiangxi Province, China
⁴Department of Endocrinology and Metabolism, Third Affiliated Hospital of Ganzhou Medical College, Ganzhou, Jiangxi Province, China
⁵Department of Biochemistry and Molecular Biology, Jiangxi Medical College of Nanchang University, Nanchang, Jiangxi Province, China

*These authors contributed equally to this work.

Corresponding author:
Ji-Xiong Xu, Department of Endocrinology and Metabolism, First Affiliated Hospital of Nanchang University, 17 Yongwaizheng Street, Nanchang 330006, Jiangxi Province, China.
Email: xujx1027@sina.com
**Conclusion:** The 2184A/G polymorphism in the AGER gene is not associated with DR in Han Chinese patients with T2DM.

**Keywords**
Receptor for advanced glycation end-products (RAGE), diabetic retinopathy, gene polymorphism, 2184A/G, type 2 diabetes mellitus, Han Chinese

Date received: 27 October 2015; accepted: 23 February 2016

**Introduction**
The increasing prevalence of type 2 diabetes mellitus (T2DM) in China is a cause for concern, with approximately 92.4 million adults aged ≥20 years reported to be affected in 2010 according to the Chinese Diabetes Society.1,2 Diabetic retinopathy (DR) is a common microvascular complication of diabetes mellitus; occurring in approximately 35.7% of patients with T2DM in China and being the principal cause of vision loss and blindness in the adult population.3

Hyperglycaemia results in the formation and accumulation of advanced glycation end-products (AGEs) as well as upregulated expression of their cellular receptor (RAGE) in the diabetic vasculature.4–6 The AGE/RAGE interaction plays an important role in the pathogenesis of diabetic microvascular complications,7 including retinal capillary degeneration, which is a characteristic of retinopathy in diabetic animal models and patients.8 Retinal capillaries are the targets of AGE-induced toxicity,9 including the induction of retinal pericyte apoptosis and the osteoblastic differentiation and calcification of pericytes.10,11 The AGE/RAGE interaction in retinal microvascular endothelial cells results in cellular activation, including: (i) the activation of nuclear factor-κB;4 (ii) increased expression of cytokines, such as vascular endothelial growth factor, which is associated with blood–retinal barrier dysfunction;12 (iii) upregulation of adhesion molecules, such as intercellular adhesion molecule, which mediates retinal capillary leukocyte adherence and inner blood–retinal barrier breakdown;13 and (iv) the induction of oxidative stress;6 all of which are involved in the pathogenesis of DR.14–16 Furthermore, the inhibition of RAGE blocks the development of DR lesions.15

Genetic polymorphisms in the advanced glycosylation end product-specific receptor (AGER) gene may alter its activity following AGE binding, which in turn might influence the development of diabetic vascular complications. Soluble RAGE (sRAGE) protein is a naturally occurring competitive inhibitor of the pathological effects induced by RAGE; it is produced by alternative splicing of the RAGE mRNA, which involves the regions between intron 7 and 9.17,18 The 2184A/G polymorphism, which is located on intron 8 of the AGER gene, has been postulated to be involved in the regulation of sRAGE production.18 The 2184A/G polymorphism was reported to be associated with antioxidant status.19 It was also reported to be associated with diabetes-associated microvascular dermatoses in patients with T2DM.20

In light of the strong association between DR and retinal oxidant status and microvascular lesions,8,9 it can be hypothesized that the 2184A/G polymorphism may contribute to the pathogenesis of DR by
influencing the AGE–sRAGE balance. The aim of this present study was to investigate the association between the 2184A/G polymorphism and DR in Han Chinese patients with T2DM. This information will be important in understanding the influence of ethnic background on the association between AGER gene polymorphisms and DR, which might provide a basis for understanding the mechanism by which RAGE contributes to DR.

Patients and methods

Study population

This cross-sectional genotyping study enrolled consecutive Han Chinese patients with T2DM in the Department of Endocrinology and Metabolism, First Affiliated Hospital of Nanchang University, Nanchang, Jiangxi Province, China between June 2010 and December 2012. Family trees were used to ensure their Han Chinese ethnic background. T2DM was diagnosed according to the 2003 American Diabetes Association diagnostic criteria for diabetes, based on a fasting blood glucose (FBG) > 7 mmol/l, a causal blood glucose > 11.1 mmol/l, or a postprandial 2-h blood glucose (2hBG) > 11.1 mmol/l following a 75-g oral glucose tolerance test, or a history of therapy for diabetes. All patients underwent a complete eye examination that included dilated retinal examination and fundus photography or fundus fluorescein angiography using a TRC-50DX Mydriatic Retinal Camera (Topcon Medical Systems, Oakland, NJ, USA), and DR was diagnosed as previously reported. The exclusion criteria were: (i) those aged < 20 or > 40 years; (ii) patients with type 1 diabetes mellitus, acute infection, the acute stage of a chronic infectious disease, inflammatory disease, uterine disorders, severe liver or renal disease; (iii) patients with eye diseases, spontaneous miscarriages or embryo transplant failures on more than three occasions; (iv) patients taking drugs or therapies that might affect reproductive or metabolic functions; (v) patients with endometrial thickness < 7 mm on the secretory transformation day; (vi) patients who were unable to comply with the study protocol. The reproductive system-related exclusion criteria were necessary because fundus fluorescein angiography is contraindicated in pregnant women.

This study was approved by the Ethics Committee of the First Affiliated Hospital of Nanchang University, Nanchang (no. CDYFY20100029) and written informed consent was obtained from all study participants. This study was performed in adherence to the principles of the Declaration of Helsinki.

Biochemical analyses

Venous blood samples were drawn from each patient by venipuncture after at least an 8-h fast for routine blood biochemical analyses that included total triglycerides (TG), total cholesterol (TC), high-density lipoprotein cholesterol (HDL-C), low-density lipoprotein cholesterol (LDL-C), fasting blood glucose, and glycosylated haemoglobin (HbA1c). TG (intra- and inter-assay coefficients of variation [CVs] of < 8% and < 9%, respectively), TC (intra- and inter-assay CVs of < 6% and < 9%, respectively), HDL-C (intra- and inter-assay CVs of < 6% and < 9%, respectively), LDL-C (intra- and inter-assay CVs of < 12% and < 14%, respectively) and fasting blood glucose (intra- and inter-assay CVs of < 10% and < 12%, respectively) were analysed using an
automated Olympus AU5421 high-volume chemistry immuno analyser (Olympus, Tokyo, Japan) according to the manufacturer’s instructions. HbA1c (intra- and inter-assay CVs of <6% and <9%, respectively) was measured using a Bio-Rad D-10™ haemoglobin analyser (Bio-Rad, Hercules, CA, USA). All biochemical analyses were carried out in triplicate.

Genotyping

For genotyping analysis, genomic DNA was extracted from 5 ml of peripheral blood collected in 1.5 mg/ml ethylenediaminetetra-acetic acid using a DNA isolation kit (Biotek, Beijing, China) according to the manufacturer’s instructions. The genomic DNA was subjected to polymerase chain reaction (PCR) with the following primers: forward primer: 5'-TAATTTCCTGCCCCATTCTG-3', reverse primer: 5'-CATCGCATCTATGCCTCCT-3' (Shanghai Sangon Biological Engineering Technology & Service, Shanghai, China). The PCR was performed in a 10 μl reaction volume containing 150 ng of genomic DNA, 0.2 μmol/l of forward and reverse primers, 0.225 U Taq DNA polymerase (Nearshore Protein Technology, Shanghai, China), 200 μmol/l of each deoxynucleotide triphosphate (Nearshore Protein Technology), and 2.0 mmol/l Mg²⁺ using an Applied Biosystems 7300 Real-Time PCR System (Applied Biosystems, Foster City, CA, USA). The amplification protocol consisted of preliminary denaturation at 94°C for 5 min, followed by 35 cycles of denaturation at 94°C for 20 s, annealing at 58°C for 30 s, and elongation at 72°C for 30 s, followed by a final elongation step at 72°C for 5 min.

For restriction fragment-length polymorphism analysis, the PCR products were digested with BsmF1 (New England Biolabs, Beverly, MA, USA) for 2 h at 65°C. Digestion products were resolved on a 2.5% agarose gel by electrophoresis at 220 V for 30 min. The 2184G minor allele mutation introduces a BsmF1 restriction site into the gene; therefore, diagnostic BsmF1 digestion produced fragments of 160 base pairs (bp) and 236 bp for the mutated minor allele 2184G, while the wild-type major allele 2184A, which does not contain this restriction site, produced a single fragment of 396 bp in length. Four representative samples from each genotype were further sequenced to confirm the overall genotyping results.

Statistical analyses

The sample size in this study was established based on a pilot study, which demonstrated genotype frequencies of 2184AG+GG of 0.20 and 0.17 for the NDR and DR groups, respectively. With a sample size ratio between the NDR and DR groups of 2:1, it was calculated that the total number of patients needed to achieve 80% power with a significance level α (two-sided α error) of 0.05 was 862.

All statistical analyses were performed using the SPSS® statistical package, version 17.0 (SPSS Inc., Chicago, IL, USA) for Windows®. Normally distributed continuous variables are presented as mean ± SD and compared with the independent samples t-test. Variables that were not normally distributed are presented as median (interquartile range) and compared with the Mann–Whitney U-test. Categorical variables and the Hardy–Weinberg equilibrium were analysed using χ²-test. Intergroup comparisons of genotype and allele distribution were analysed using Fisher’s exact test and χ²-test, respectively. A two-sided P-value <0.05 was considered statistically significant.

Results

A total of 943 patients with T2DM were enrolled in the study, including 285 patients
in the DR group and 658 in the NDR group, which was an adequate sample size based on the power calculation. The demographic and clinical characteristics for the DR and NDR groups are shown in Table 1. There were no significant differences in age, sex distribution, body mass index, TC, DBP, HbA1c, FBG, 2hBG, TG, LDL-C, and HDL-C between the two groups. The duration of T2DM and systolic blood pressure were significantly increased in the DR group compared with the NDR group ($P < 0.05$ for both comparisons).

The genotype frequencies of the 2184A/G polymorphism in the DR and NDR groups were in Hardy–Weinberg equilibrium. Table 2 shows the allele and genotype frequency distribution of the 2184A/G polymorphism in the NDR and DR groups. There were no significant differences in the allele (A and G) and genotype (AA, AG, and GG) frequencies of the 2184A/G polymorphism between the DR and NDR groups.

### Discussion

A number of single nucleotide polymorphisms (SNPs) have been identified in the coding and noncoding regions of the AGER gene. Many studies have investigated the association between various SNPs in the AGER gene with DR, but the results of these association studies have been inconsistent or even directly conflicting. For example, some studies suggested that the AGER polymorphisms $-429$ T/C, $-374$ T/A, Gly82Ser, 1704G/T, and 2245G/A are associated with DR, while other studies, including a previous study from our group, did not support a significant association between these polymorphisms.
and DR.31–37 These studies also suggested that these AGER gene polymorphisms have different distributions in different ethnic populations, which may be associated with the different contributions of these mutations against different ethnic backgrounds.35,36 A significant association between the Gly82Ser polymorphism in the AGER gene with DR has been reported in Asian Indians38,39 and Asian Chinese29 with T2DM. In contrast, an absence of a significant association between the Gly82Ser, 1704G/T, and 2184A/G AGER gene polymorphisms and DR has been reported in Malaysian32 and Japanese37 populations. For the 2184A/G polymorphism, a few studies reported that 2184A/G polymorphisms were not associated with DR in patients with T2DM.31,32,40 Of note, a recent report even showed no association between 2184A/G polymorphisms and DR in a Chinese population.40 As the diverse nationalities within the very large Chinese population might bring about complexity in the analysis, this present study performed a cross-sectional analysis to observe the correlation between 2184A/G polymorphisms and DR in a Han Chinese population that is representative of the majority of the Chinese population.

In this present study, there were no statistically significant differences in the genotype and allele frequencies of the 2184A/G polymorphism among the DR and NDR groups, indicating that the 2184A/G polymorphism in the AGER gene is not associated with DR in Han Chinese patients with T2DM. The results of this present study were similar to those previously reported31,32,40 Two important differences exist between this present study and a previous study that also reported on a Chinese population:40 (i) this present study exclusively assessed a Han Chinese population, while the previous study evaluated a general Chinese population; and (ii) the present study used polymerase chain reaction–restriction fragment-length polymorphism, while the previous study utilized chip-based matrix-assisted laser desorption ionization time-of-flight mass spectrometry for genotypic analysis. Furthermore, another study reported that the 2184A/G polymorphism in the AGER gene was associated with diabetes-associated microvascular dermatoses in patients with T2DM.20 This finding and that of the present study suggest that there is heterogeneity in the genetic susceptibility to diabetes-associated microvascular complications among different organs.

The present study had some limitations. First, it did not measure the serum levels of RAGE protein, so it was not able to determine if the serum levels of RAGE protein changed concomitantly with the presence of the 2184A/G polymorphism in the AGER gene. Secondly, because of the limited sample size, it was not possible to classify the patients with DR into non-proliferative retinopathy and proliferative retinopathy for further subgroup investigations. Thirdly, as this

| Genotypes and alleles | NDR  | DR  | χ²-test |
|-----------------------|------|-----|---------|
| Genotype              |      |     |         |
| AA                    | 540 (82.1) | 240 (84.2) | 1.136 |
| AG                    | 109 (16.6)  | 43 (15.1)  |       |
| GG                    | 9 (1.4)   | 2 (0.7)    |       |
| Allele                |      |     |         |
| A                     | 1189 (90.3) | 523 (91.8) | 0.937 |
| G                     | 127 (9.7)  | 47 (8.2)   |       |
| HWE                   | 0.111 | 0.395 |         |

Data presented as n of patients (%) or n of alleles (%). No significant between-group differences (P ≥ 0.05); genotype and allele distribution were analysed using Fisher’s exact test and χ²-test, respectively. NDR, no diabetic retinopathy; HWE, Hardy–Weinberg equilibrium.
was a cross-sectional study, it was not possible to investigate the progression of DR. Further prospective studies are necessary to confirm the association between the 2184A/G polymorphism in the \textit{AGER} gene and the serum levels of RAGE protein with the presence of DR in patients with T2DM.

In conclusion, the findings of this present study suggest that the 2184A/G polymorphism in the \textit{AGER} gene is not associated with diabetic retinopathy in Han Chinese patients with type 2 diabetes mellitus.

Acknowledgements

The authors would like to thank all of the patients who participated in this study.

Declaration of conflicting interests

The authors declare that there are no conflicts of interest.

Funding

The study was supported by grants from the National Natural Science Funds of China (no. 81160105, no. 81460018), Jiangxi Provincial Department of Education Scientific Research Funds of China (no. GJJ08088, no. GJJ13145) and the Jiangxi Provincial Natural Science Funds of China (no. 20114BAB205006).

References

1. Hu Y, Teng W, Liu L, et al. Prevalence and risk factors of diabetes and diabetic retinopathy in Liaoning province, China: a population-based cross-sectional study. \textit{PLoS One} 2015; 10: e0121477.
2. Yang SH, Dou KF and Song WJ. Prevalence of diabetes among men and women in China. \textit{N Engl J Med} 2010; 362: 2425–2426.
3. Chinese Diabetes Society. China Guideline for Type 2 Diabetes: 2010, Beijing Medical University Press, 2011.5, http://guide.medlive.cn/guideline/371 (2010, accessed 9 March 2016).
4. Stitt AW. AGEs and diabetic retinopathy. \textit{Invest Ophthalmol Vis Sci} 2010; 51: 4867–4874.
5. Pachydaki SI, Tari SR, Lee SE, et al. Upregulation of RAGE and its ligands in proliferative retinal disease. \textit{Exp Eye Res} 2006; 82: 807–815.
6. Yamagishi S, Ueda S, Matsui T, et al. Role of advanced glycation end products (AGEs) and oxidative stress in diabetic retinopathy. \textit{Curr Pharm Des} 2008; 14: 962–968.
7. Schmidt AM and Stern DM. RAGE: a new target for the prevention and treatment of the vascular and inflammatory complications of diabetes. \textit{Trends Endocrinol Metab} 2000; 11: 368–375.
8. Gardiner TA, Archer DB, Curtis TM, et al. Arteriolar involvement in the microvascular lesions of diabetic retinopathy: implications for pathogenesis. \textit{Microcirculation} 2007; 14: 25–38.
9. Li W, Yanoff M, Jian B, et al. Altered mRNA levels of antioxidant enzymes in pre-apoptotic pericytes from human diabetic retinas. \textit{Cell Mol Biol (Noisy-le-grand) 1999; 45: 59–66.}
10. Chen BH, Jiang DY and Tang LS. Advanced glycation end-products induce apoptosis involving the signaling pathways of oxidative stress in bovine retinal pericytes. \textit{Life Sci} 2006; 79: 1040–1048.
11. Yamagishi S, Fujimori H, Yonekura H, et al. Advanced glycation endproducts accelerate calcification in microvascular pericytes. \textit{Biochem Biophys Res Commun} 1999; 258: 353–357.
12. Canning P, Glenn JV, Hsu DK, et al. Inhibition of advanced glycation and absence of galectin-3 prevent blood-retinal barrier dysfunction during short-term diabetes. \textit{Exp Diabetes Res} 2007; 2007: 51837.
13. Moore TC, Moore JE, Kaji Y, et al. The role of advanced glycation end products in retinal microvascular leukostasis. \textit{Invest Ophthalmol Vis Sci} 2003; 44: 4457–4464.
14. Barile GR, Pachydaki SI, Tari SR, et al. The RAGE axis in early diabetic retinopathy. \textit{Invest Ophthalmol Vis Sci} 2005; 46: 2916–2924.
15. Li G, Tang J, Du Y, et al. Beneficial effects of a novel RAGE inhibitor on early diabetic
retinopathy and tactile allodynia. *Mol Vis* 2011; 17: 3156–3165.

16. Yamagishi S, Amano S, Inagaki Y, et al. Advanced glycation end products-induced apoptosis and overexpression of vascular endothelial growth factor in bovine retinal pericytes. *Biochem Biophys Res Commun* 2002; 290: 973–978.

17. Yonekura H, Yamamoto Y, Sakurai S, et al. Novel splice variants of the receptor for advanced glycation end-products expressed in human vascular endothelial cells and pericytes, and their putative roles in diabetes-induced vascular injury. *Biochem J* 2003; 370(Pt 3): 1097–1109.

18. Schlueter C, Hauke S, Flohr AM, et al. Tissue-specific expression patterns of the RAGE receptor and its soluble forms—a result of regulated alternative splicing? *Biochim Biophys Acta* 2003; 1630: 1–6.

19. Kankova K, Márová I, Záhejský J, et al. Polymorphisms 1704G/T and 2184A/G in the RAGE gene are associated with antioxidant status. *Metabolism* 2001; 50: 1152–1160.

20. Kankova K, Záhejský J, Márová I, et al. Polymorphisms in the RAGE gene influence susceptibility to diabetes-associated microvascular dermatoses in NIDDM. *J Diabetes Complications* 2001; 15: 185–192.

21. Genuth S, Alberti KG, Bennett P, et al. Follow-up report on the diagnosis of diabetes mellitus. *Diabetes Care* 2003; 26: 3160–3167.

22. Grading diabetic retinopathy from stereoscopic color fundus photographs—an extension of the modified Airlie House classification. ETDRS report number 10. Early Treatment Diabetic Retinopathy Study Research Group. *Ophthalmology* 1991; 98(5 Suppl): 786–806.

23. Cai W, Li J, Xu JX, et al. Association of 2184AG polymorphism in the RAGE gene with diabetic nephropathy in Chinese patients with type 2 diabetes. *J Diabetes Res* 2015; 2015: 310237.

24. Hudson BI, Stickland MH and Grant PJ. Identification of polymorphisms in the receptor for advanced glycation end-products (RAGE) gene: prevalence in type 2 diabetes and ethnic groups. *Diabetes* 1998; 47: 1155–1157.

25. Hudson BI, Stickland MH, Futers TS, et al. Effects of novel polymorphisms in the RAGE gene on transcriptional regulation and their association with diabetic retinopathy. *Diabetes* 2001; 50: 1505–1511.

26. Lindholm E, Bakhtadze E, Sjögren M, et al. The −374 T/A polymorphism in the gene encoding RAGE is associated with diabetic nephropathy and retinopathy in type 1 diabetic patients. *Diabetologia* 2006; 49: 2745–2755.

27. Ramprasad S, Radha V, Mathias RA, et al. RAGE gene promoter polymorphisms and diabetic retinopathy in a clinic-based population from South India. *Eye (Lond)* 2007; 21: 395–401.

28. Balasubbu S, Sundaresan P, Rajendran A, et al. Association analysis of nine candidate gene polymorphisms in Indian patients with type 2 diabetic retinopathy. *BMC Med Genet* 2010; 11: 158.

29. Zhang HM, Chen LL, Wang L, et al. Association of 1704G/T and G82S polymorphisms in the receptor for advanced glycation end products gene with diabetic retinopathy in Chinese population. *J Endocrinol Invest* 2009; 32: 258–262.

30. Ng ZX, Kuppusamy UR, Tajunisah I, et al. 2245G/A polymorphism of the receptor for advanced glycation end-products (RAGE) gene is associated with diabetic retinopathy in the Malaysian population. *Br J Ophthalmol* 2012; 96: 289–292.

31. Kanková K, Beránek M, Hájek D, et al. Polymorphisms 1704G/T, 2184A/G, and 2245G/A in the rage gene are not associated with diabetic retinopathy in NIDDM: pilot study. *Retina* 2002; 22: 119–121.

32. Ng ZX, Kuppusamy UR, Poh R, et al. Lack of association between Gly82Ser, 1704G/T and 2184A/G of RAGE gene polymorphisms and retinopathy susceptibility in Malaysian diabetic patients. *Genet Mol Res* 2012; 11: 455–461.

33. Globocnik Petrovic M, Stelhovnik K, Peterlin B, et al. The −429 T/C and −374 T/A gene polymorphisms of the receptor of advanced glycation end products gene are not risk factors for diabetic retinopathy in
Caucasians with type 2 diabetes. *Klin Monbl Augenheilkd* 2003; 220: 873–876.

34. Ng ZX, Kuppusamy UR, Tajunisah I, et al. Association analysis of $-429T/C$ and $-374T/A$ polymorphisms of receptor of advanced glycation end products (RAGE) gene in Malaysian with type 2 diabetic retinopathy. *Diabetes Res Clin Pract* 2012; 95: 372–377.

35. Xu JX, Xu BL, Yang MG, et al. $-429T/C$ and $-374T/A$ polymorphisms of RAGE gene promoter are not associated with diabetic retinopathy in Chinese patients with type 2 diabetes. *Diabetes Care* 2003; 26: 2696–2697.

36. Liu L and Xiang K. RAGE Gly82Ser polymorphism in diabetic microangiopathy (Letter). *Diabetes Care* 1999; 22: 646.

37. Yoshioka K, Yoshida T, Takakura Y, et al. Relation between polymorphisms G1704T and G82S of RAGE gene and diabetic retinopathy in Japanese type 2 diabetic patients. *Intern Med* 2005; 44: 417–421.

38. Kumaramanickavel G, Ramprasad VL, Sripriya S, et al. Association of Gly82Ser polymorphism in the RAGE gene with diabetic retinopathy in type II diabetic Asian Indian patients. *J Diabetes Complications* 2002; 16: 391–394.

39. Vanita V. Association of RAGE (p.Gly82Ser) and MnSOD (p.Val16Ala) polymorphisms with diabetic retinopathy in T2DM patients from north India. *Diabetes Res Clin Pract* 2014; 104: 155–162.

40. Yang L, Wu Q, Li Y, et al. Association of the receptor for advanced glycation end products gene polymorphisms and circulating RAGE levels with diabetic retinopathy in the Chinese population. *J Diabetes Res* 2013; 2013: 264579.